Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

0.2100 UNCHANGED
Streaming Delayed Price Updated: 12:54 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.2100
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2100
Today's Range 0.2100 - 0.2100
52wk Range 0.1680 - 1.052
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.   
Via Benzinga

Performance

YTD
-8.70%
-8.70%
1 Month
-20.75%
-20.75%
3 Month
-28.38%
-28.38%
6 Month
-40.00%
-40.00%
1 Year
-77.79%
-77.79%

More News

Read More
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Via Benzinga
Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
Via Benzinga
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Via Benzinga
Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
Via Benzinga
EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility
Via Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Via Benzinga
MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production
Via Benzinga
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Via Benzinga
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Via Benzinga
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Via Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Via Benzinga
A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability
Via Benzinga
Awakn Life Sciences Corp Shares Rally 77% After Earning ILAP Expedited Approval Pathway For Its Ketamine-Assisted AUD Therapeutic ($AWKNF)
Via AB Newswire
Exposures Product Safety
Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status
Via Benzinga
Awakn Life Sciences Corp Earns Global AUD Treatment Interest With A New Class Of Psychedelics-Based Therapeutic ($AWKNF)
Via AB Newswire
Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing
Via Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
Via Benzinga
6 Largest Psychedelic Drug Stocks Were -20% In December
Via Talk Markets
Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.